ENN-0403 is under clinical development by Ennovabio and currently in Phase I for Diabetic Retinopathy. According to GlobalData, Phase I drugs for Diabetic Retinopathy have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ENN-0403’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ENN-0403 overview

ENN-0403 is under development for the treatment of non-alcoholic steatohepatitis (NASH), diabetic retinopathy and pulmonary fibrosis. It is administered through oral route in the form of capsules.

Ennovabio overview

Ennovabio, a pharmaceutical company that focuses on creating drugs targeting brain glioma. The company is headquartered in China.

For a complete picture of ENN-0403’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.